SCHEMBL21189257

SCHEMBL21189257

COC(=O)NC1CCOc2c1ccc(F)c2C(=O)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 8/20 0.43
GLA P06280 1/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 4/20 0.41
HTT P42858 1/20 0.41
TP53 P04637 1/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189535 1.00 MEN1 (0.44) MEN1KMT2AALDH1A1SMN1; SMN2GLA
SCHEMBL21189268 0.91 RAB9A (0.42) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL21189237 0.91 RAB9A (0.42) ALDH1A1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL21189258 0.90 SMN1; SMN2 (0.40) MEN1KMT2AALDH1A1SMN1; SMN2GLA
SCHEMBL19973567 0.89 KMT2A (0.46) MEN1KMT2AALDH1A1SMN1; SMN2NPC1
SCHEMBL19973566 0.89 KMT2A (0.46) MEN1KMT2AALDH1A1SMN1; SMN2NPC1
SCHEMBL21189278 0.89 FADS1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2NPC1
SCHEMBL19973470 0.89 MEN1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2NPC1
SCHEMBL19973471 0.89 MEN1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2NPC1
SCHEMBL21189276 0.83 NPC1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS MEN1 1933/4885KMT2A 155/4885ALDH1A1 3241/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS MEN1 1933/4885KMT2A 155/4885ALDH1A1 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.